Erleva contains the active ingredient Erlotinib, a tyrosine kinase inhibitor prescribed for patients with non-small cell lung cancer (NSCLC) as first-line or maintenance therapy, and second or third-line therapy for advanced NSCLC. This is not a cure for lung cancer, but Erleva and the generic alternative Erlotinib can slow tumor growth and reduce the ability of cancer cells to reproduce.
Role of Erleva in Your Body
Many cancer cells have a structure called epidural growth factor receptor (EGFR) on their surface that allows proteins to attach to cells. This action then triggers a tyrosine kinase (an enzyme in the cell) that sends a growth signal in the cell to allow the cancer cell to multiply. Erleva prevents EGFR from being activated by tyrosine kinases, and the number of cancer cells begins to decline because they cannot grow and multiply...Read More